Robert E. Schoen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert E. Schoen has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Lynda Dzubinski
11Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
154 shared publications - Brenda Diergaarde
Department of Human Genetics, School of Public Health University of Pittsburgh Pittsburgh Pennsylvania USA
128 shared publications - Jane C. Figueiredo
Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA
109 shared publications - Olivera J. Finn
Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
96 shared publications - Eva Szabo
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
95 shared publications - Paul J. Limburg
Abbott, Madison, Wisconsin
95 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216/anti-PD-1 combination enhances antitumor immune response in Mlh1-KO CT26 tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216/anti-PD-1 combination enhances antitumor immune response in Mlh1-KO CT26 tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
HRO761/anti-PD-1 combination enhances antitumor immune response in Mlh1-KO CT26 tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
HRO761/anti-PD-1 combination enhances antitumor immune response in Mlh1-KO CT26 tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
EccDNA mediates immune activation in WRN-depleted HCT116 cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
EccDNA mediates immune activation in WRN-depleted HCT116 cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
Colorectal cancer with microsatellite instability (MSI) is often treated with immune checkpoint inhibitors (ICI), such as anti–PD-1 antibodies. However, a substantial fraction of MSI colorectal cancers do not respond to ICIs. Recent studies have identified the DNA helicase Werner (WRN) as a synthetic lethal target in MSI cancer cells, leading to the development of several small-molecule WRN inhibitors that are currently in clinical trials. In this study, we found that targeting WRN in MSI colorectal cancer cells triggered a robust antitumor immune response. Cell death induced by WRN inhibition was selective in MSI colorectal cancer cells and led to the release of extrachromosomal circular DNA (eccDNA), which directly stimulated immune cell activation and cytokine production. The deletion of nuclear ligase LIG3, a key mediator of eccDNA biogenesis, abolished the antitumor and immunogenic effects of WRN inhibition in MSI colorectal cancer cells and tumors. Furthermore, WRN inhibition potentiated anti–PD-1 therapy in MSI colorectal cancer models, including syngeneic mouse tumors and patient-derived tumor organoids. Together, these results reveal the eccDNA-mediated immunogenic effects of WRN inhibition in MSI colorectal cancer, further strengthening the rationale for combining WRN inhibitors with ICIs. Significance:Extrachromosomal circular DNA release induced by WRN inhibition in colorectal cancer cells with microsatellite instability stimulates immune cell activation and cytokine production, which can be leveraged to enhance the efficacy of immunotherapy.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
Colorectal cancer with microsatellite instability (MSI) is often treated with immune checkpoint inhibitors (ICI), such as anti–PD-1 antibodies. However, a substantial fraction of MSI colorectal cancers do not respond to ICIs. Recent studies have identified the DNA helicase Werner (WRN) as a synthetic lethal target in MSI cancer cells, leading to the development of several small-molecule WRN inhibitors that are currently in clinical trials. In this study, we found that targeting WRN in MSI colorectal cancer cells triggered a robust antitumor immune response. Cell death induced by WRN inhibition was selective in MSI colorectal cancer cells and led to the release of extrachromosomal circular DNA (eccDNA), which directly stimulated immune cell activation and cytokine production. The deletion of nuclear ligase LIG3, a key mediator of eccDNA biogenesis, abolished the antitumor and immunogenic effects of WRN inhibition in MSI colorectal cancer cells and tumors. Furthermore, WRN inhibition potentiated anti–PD-1 therapy in MSI colorectal cancer models, including syngeneic mouse tumors and patient-derived tumor organoids. Together, these results reveal the eccDNA-mediated immunogenic effects of WRN inhibition in MSI colorectal cancer, further strengthening the rationale for combining WRN inhibitors with ICIs. Significance:Extrachromosomal circular DNA release induced by WRN inhibition in colorectal cancer cells with microsatellite instability stimulates immune cell activation and cytokine production, which can be leveraged to enhance the efficacy of immunotherapy.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216 induces antitumor immune response in Mlh1-KO CT26 tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216 induces antitumor immune response in Mlh1-KO CT26 tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
HRO761 induces antitumor immune response in Mlh1-KO CT26 tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
HRO761 induces antitumor immune response in Mlh1-KO CT26 tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
WRN knockdown induces DNA damage and apoptosis in human MSI CRC cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
WRN knockdown induces DNA damage and apoptosis in human MSI CRC cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216/anti-PD-1 combination enhances immune activation in MSI CRC patient-derived organoids.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
ML216/anti-PD-1 combination enhances immune activation in MSI CRC patient-derived organoids.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
WRN knockdown induces DNA damage and apoptosis in Mlh1-KO CT26 cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
WRN knockdown induces DNA damage and apoptosis in Mlh1-KO CT26 cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
EccDNA mediates immune activation in WRN-depleted Mlh1-KO CT26 cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release
EccDNA mediates immune activation in WRN-depleted Mlh1-KO CT26 cells.